Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.
about
The changing landscape of biosimilars in rheumatologyThe safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used aCT-P13: design, development, and place in therapySwitching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe.The Role of Biosimilars in Inflammatory Bowel Disease.Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product.CT-P13 in the treatment of rheumatoid arthritis.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.Interchangeability of Biosimilars: A European Perspective.Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.Comparative effectiveness of the biosimilar CT-P13.Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.The road from development to approval: evaluating the body of evidence to confirm biosimilarity.Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence.Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study.The nocebo effect challenges the non-medical infliximab switch in practice.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis.The biosimilars journey: current status and ongoing challengesA descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish populationNon-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar AgentNon-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
P2860
Q26766515-CDE75DEB-D6D4-4ED6-BD26-30F59ABE9CDAQ30397234-34CFF84D-F955-4039-A837-EABF7D5C9659Q31105857-F66EA5BA-64D6-4211-AFA2-D33F98CD628FQ33803728-B552F914-E3BC-403B-AA41-F0ACA580682EQ33840949-B2A48F05-4749-4E20-A981-C61C18404C76Q33881234-C0CA9587-7E64-41BB-A33F-256F5A7FAB3EQ37453045-02C23BEE-70AC-4638-A864-C1E90213B2B3Q37540190-68E145FB-112E-4025-B082-6E92277F1988Q37698663-9064510D-1783-4AE3-89FD-73A3B2BCAB0BQ38676104-2BFDB206-1B34-493E-9F67-0D883FE79623Q38708927-ED76110B-7724-48DD-B6E2-FABBBC711233Q38953729-6A499ADB-3A0A-4DC1-B96E-9EED5EC04968Q39000780-E2D8A07A-8489-4A54-8276-73E51BDC0FB3Q39184810-6E54F613-C163-4A31-AEF6-4F66873D5F11Q40233716-C78B7181-C4C9-48A5-B162-191F7C8672A4Q42360803-3FDEFC1D-7F97-4538-9341-BE09DFBB3647Q47106974-3B03C4BC-C295-41C1-A1E5-7E04BD64AA6BQ47418286-14B14184-431D-4D4F-BCC7-214B2ED70A10Q47633961-5A6808C4-A5D7-42C8-9B17-FE49E462571AQ47656264-3A270336-FBDE-44A0-BDBB-65FA15F90AFAQ47688424-8BD7253C-3FBE-4585-B0E2-7B380A96362FQ47807650-A8334686-DCF5-41F0-95AA-3F27EFDD7AFAQ47950956-D32D52C7-E58A-44DE-9060-4C9379AD05B3Q48092457-A974590D-51FD-4A6D-AA94-FAE2C4DF7314Q48216426-9C5D9723-7B31-48C2-9BC4-78F750DE4656Q48309038-F9F1CADE-3376-4221-8FEE-53919227D5CDQ49721192-1EA6C0C0-3668-428F-ABCD-311C6CDD873DQ49979586-D97D6BC0-A0B9-4BD9-A196-DFC4E5CCF523Q51022840-F6C0F618-6368-4785-8428-4FD6F7793995Q52651099-B4C6C625-3984-445A-8C38-D6C1A624F79BQ55693631-0A8530CF-F44B-4EC0-9930-2720DC2F04A5Q57298628-78752546-3B7B-4C46-8553-19748B4BF357Q57484897-C493055C-18B6-4120-AE86-1CF819A7FBDAQ58795531-C80CB2CF-CC35-4D2C-A248-092982B388DFQ58798380-28866682-FFC4-49A7-AC72-44D82EC10060
P2860
Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Clinical effectiveness of CT-P ...... rospective observational data.
@ast
Clinical effectiveness of CT-P ...... rospective observational data.
@en
type
label
Clinical effectiveness of CT-P ...... rospective observational data.
@ast
Clinical effectiveness of CT-P ...... rospective observational data.
@en
prefLabel
Clinical effectiveness of CT-P ...... rospective observational data.
@ast
Clinical effectiveness of CT-P ...... rospective observational data.
@en
P2093
P2860
P1476
Clinical effectiveness of CT-P ...... rospective observational data.
@en
P2093
Arto Kokko
Elena Nikiphorou
Hannu Kautiainen
Juha Asikainen
Pekka Hannonen
Tuomas Rannio
Tuulikki Sokka
P2860
P304
P356
10.1517/14712598.2015.1103733
P407
P577
2015-11-07T00:00:00Z